Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. Issue 6 (20th October 2020)

• Record Type: Journal Article
• Authors: Bonanni, Bernardo; Serrano, Davide; Maisonneuve, Patrick; Veronesi, Giulia; Johansson, Harriet; Aristarco, Valentina; Varricchio, Clara; Cazzaniga, Massimiliano; Lazzeroni, Matteo; Rampinelli, Cristiano; Bellomi, Massimo; Vecchi, Manuela; Spaggiari, Lorenzo; Vornik, Lana; Brown, Powel H; Beavers, Therese; Guerrieri-Gonzaga, Aliana; Szabo, Eva
• Is Part Of: JNCI cancer spectrum. Volume 4:Issue 6(2020)
• Publication Date: 2020-10-20
• DOI: 10.1093/jncics/pkaa096
• Languages: English
• ISSNs: 2515-5091

Abstract

Abstract: Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin's anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual low-dose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12 months of treatment (-0.12 mm [SD = 1.55 mm] and +0.30 mm [SD= 2.54 mm], respectively; 2-sided P = .33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.